Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ironwood Pharma (IRWD) Misses Q4 EPS by 2c
February 16, 2023 7:05 AM ESTIronwood Pharma (NASDAQ: IRWD) reported Q4 EPS of $0.27, $0.02 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $107.2 million versus the consensus estimate of $114.93 million.
For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.
... More